These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 543901)

  • 1. Elimination kinetics of mezlocillin in normal and impaired renal function including the effects of dialysis.
    Kosmidis J; Doundoulaki P; Stathakis C; Zerefos N; Bounia A; Daikos GK
    Arzneimittelforschung; 1979; 29(12a):1960-2. PubMed ID: 543901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison between the pharmacokinetic properties of mezlocillin when given intravenously as a bolus injection or as an infusion.
    Ohlsson H; Bergan T
    Arzneimittelforschung; 1979; 29(12a):1958-9. PubMed ID: 543900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pharmacokinetics of intramuscular mezlocillin in patients with normal and impaired renal function (author's transl)].
    Brogard JM; Comte F; Kopferschmitt J; Dorner M; Lavillaureix
    Nouv Presse Med; 1982 Feb; 11(5 Pt 2):340-6. PubMed ID: 6460973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pharmacokinetics of intravenous mezlocillin in patients with normal and impaired renal function (author's transl)].
    Cano JP; Rigault JP; Gevaudan MJ; Saingra S; Murisasco A; Charpin J
    Nouv Presse Med; 1982 Feb; 11(5 Pt 2):335-9. PubMed ID: 6460972
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of mezlocillin during haemodialysis.
    Thorsteinsson SB; Steingrimsson O; Asmundsson P; Bergan T
    Scand J Infect Dis Suppl; 1981; 29():59-63. PubMed ID: 6458883
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pharmacokinetics of mezlocillin. Comparison with ampicillin and influence of probenecid (author's transl)].
    Verbist L; Tjandramaga TB; Verbesselt R; de Schepper PJ
    Nouv Presse Med; 1982 Feb; 11(5 Pt 2):347-52. PubMed ID: 6460974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overview of acylureidopenicillin pharmacokinetics.
    Bergan T
    Scand J Infect Dis Suppl; 1981; 29():33-48. PubMed ID: 7031864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Mezlocillin concentrations in human bone tissue].
    Vent J
    Arzneimittelforschung; 1979; 29(12a):1969-71. PubMed ID: 543904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of impaired renal function, hemodialysis, and peritoneal dialysis on the pharmacokinetics of mezlocillin.
    Kampf D; Schurig R; Weihermüller K; Förster D
    Antimicrob Agents Chemother; 1980 Jul; 18(1):81-7. PubMed ID: 6448024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Degradation of Azlocillin and Mezlocillin / I. Behaviour in biological material and buffer (author's transl)].
    Gundert-Remy U; Weber E
    Arzneimittelforschung; 1981; 31(12):2041-4. PubMed ID: 6460506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cerebrospinal fluid penetration of mezlocillin.
    Modai J; Pierre J; Bergogne-Berezin E; Avril MF
    Arzneimittelforschung; 1979; 29(12a):1967-9. PubMed ID: 543903
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of azlocillin in children with cystic fibrosis.
    Bergan T; Michalsen H
    Arzneimittelforschung; 1979; 29(12a):1955-7. PubMed ID: 543899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and pharmacodynamics of lobaplatin (D-19466) in patients with advanced solid tumors, including patients with impaired renal of liver function.
    Welink J; Boven E; Vermorken JB; Gall HE; van der Vijgh WJ
    Clin Cancer Res; 1999 Sep; 5(9):2349-58. PubMed ID: 10499604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interactions between mezlocillin and sisomicin in vitro and in patients with normal and various degrees of impaired renal function.
    Kampf D; Schurig R; Bergs A; Förster D
    Clin Nephrol; 1983 Jan; 19(1):37-44. PubMed ID: 6219847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disposition kinetics of dibekacin in normal subjects and in patients with renal failure.
    Arancibia A; Chávez J; Ibarra R; Ruiz I; Icarte A; Thambo S; Chávez H
    Int J Clin Pharmacol Ther Toxicol; 1987 Jan; 25(1):38-43. PubMed ID: 3557728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mezlocillin pharmacokinetics after single intravenous doses to patients with varying degrees of renal function.
    Frimodt-Möller N; Maigaard S; Toothaker RD; Bundtzen RW; Brodey MV; Craig WA; Welling PG; Madsen PO
    Antimicrob Agents Chemother; 1980 Apr; 17(4):599-607. PubMed ID: 6446877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of the new broad spectrum penicillin CP-33994-2.
    Bergan T; Brodwall EK; Orjavik O
    Arzneimittelforschung; 1980; 30(7):1144-7. PubMed ID: 7191297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of childhood meningitis with mezlocillin.
    Llorens-Terol J; Lobato A; Adam D
    Arzneimittelforschung; 1979; 29(12a):2001-2. PubMed ID: 543912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of mezlocillin in patients with kidney impairment: special reference to hemodialysis and dosage adjustments in relation to renal function.
    Brogard JM; Comte F; Spach MO; Lavillaureix J
    Chemotherapy; 1982; 28(5):318-26. PubMed ID: 6216076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Local tolerance of i.m. mezlocillin injection.
    Belli L; Gandolfo S; Varela M; Gennaro EA
    Arzneimittelforschung; 1979; 29(12a):1985-7. PubMed ID: 543907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.